Imunon (IMNN)
NASDAQ:IMNN
Earnings Data
Report Date
May 18, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed strong, potentially transformative clinical momentum driven by a robust Phase II overall survival signal (14.7 months) and faster-than-expected Phase III enrollment, supported by translational data, publications, CRO support and cost discipline. However, near-term financing risk is acute (cash of $8.8M with runway into H2 2026), the registrational timeline extends to 2029 absent an early interim readout, and some scientific endpoints (MRD) remain exploratory. Management is actively pursuing financing and partnerships and has taken cost-saving measures to extend the runway, but successful execution of funding and completion of the Phase III program are critical next steps.Company Guidance
Transformational Phase II Overall Survival Benefit
OVATION 2 final analysis reported a 14.7-month median overall survival (OS) benefit versus control (prior readouts: 11.1 months and 13 months), representing continued improvement across analyses and a clinically meaningful absolute OS gain.
Large PARP-Inhibitor Subgroup Benefit
Patients in OVATION 2 who received PARP inhibitors as maintenance in addition to IMNN-001 demonstrated a median OS increase of more than two years (greater than 24 months), indicating a potentially profound benefit in this subgroup.
Phase III (OVATION 3) Enrollment Momentum
OVATION 3 is enrolling ahead of plan with 7 sites actively enrolling, ~43 additional centers in evaluation/start-up, and a goal of ~80 patients enrolled within 12 months. Several early sites are enrolling at up to ~1 patient/month versus the protocol assumption of 0.3 patients/month (~3x the assumed rate).
Regulatory and Trial Design De-risking
FDA endorsement of overall survival as the primary endpoint and an adaptive Phase III design with interim analyses (95% power for OS primary) provide a de-risked path toward potential regulatory approval and accelerated timelines if strong early efficacy is observed.
Supportive Translational and MRD Data
MRD Phase II study (enrollment capped at 30 patients) and translational analyses demonstrate preferential peritoneal macrophage uptake, tumor microenvironment remodeling, durable IL-12/IFN-γ expression, complete pathological responses in some cases, and favorable tolerability — aligning with OVATION 2 OS signals.
Scientific Recognition and Publications
Key data were presented at major forums (including ASCO 2025), OVATION 2 results were published in Gynecological Oncology, and the company hosted a successful R&D Day — increasing investigator and investor interest.
Improved Cost Discipline and Operating Efficiency
R&D spending for 2025 was $7.8M (reduced vs. 2024 due to completion/optimization of studies and focused Phase III spend). General & administrative expenses decreased 8% year-over-year. Net loss improved to $14.5M from $18.6M in 2024 (~22% reduction). Strategic reorganization in Feb 2026 and manufacturing efficiencies were implemented to extend runway and focus resources on OVATION 3.
Operational Supports in Place
Company contracted a global CRO to accelerate site activation and start-up; returning OVATION 2 investigators and new top-tier centers are proactively joining OVATION 3, supporting faster roll-out.
IMNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMNN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $2.88 | $2.94 | +2.08% |
Nov 13, 2025 | $3.95 | $4.16 | +5.32% |
Aug 05, 2025 | $8.00 | $7.62 | -4.78% |
May 12, 2025 | $10.43 | $10.64 | +1.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Imunon (IMNN) report earnings?
Imunon (IMNN) is schdueled to report earning on May 18, 2026, TBA (Confirmed).
What is Imunon (IMNN) earnings time?
Imunon (IMNN) earnings time is at May 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMNN EPS forecast?
Currently, no data Available